GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori

Fertility and Sterility

Volumn 91, Issue 4 SUPPL., 2009, Pages 1378-1380

  Orvieto, Raoul ^a,b   Homburg, Roy ^a   Meltcer, Simion ^a   Rabinson, Jacob ^a   Anteby, Eyal Y ^a,b   Scharf, Shimon ^a,b  

^a BARZILAI MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; TRIPTORELIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ESTROGENS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OOCYTE RETRIEVAL; OVULATION INDUCTION; PATIENT SATISFACTION; PREGNANCY; PREGNANCY RATE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; TRIPTORELIN;

EID: 63249120983     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.04.028     Document Type: Article

References (9)

1. Penzias A.S. Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reprod Biomed Online 9 (2004) 43-46
2. Al-Inany H., Abou-Setta A.M., and Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 14 (2007) 640-649
3. Ludwig M., Katalinic A., and Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 265 (2001) 175-182
4. Fauser B.C., and Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?. Fertil Steril 83 (2005) 1607-1611
5. Griesinger G., Felberbaum R., and Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German National IVF Registry. Hum Reprod 20 (2005) 2373-2375
6. Orvieto R., Rabinson J., Meltzer S., Homburg R., Anteby E., and Zohav E. GnRH agonist versus GnRH antagonist in ovarian stimulation: Is the emperor naked?. Clin Exp Obstet Gynecol 33 (2006) 197-199
7. Orvieto R, Meltcer S, Rabinson J, Zohav E, Anteby EY, Nahum R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity. Fertil Steril. In press.
8. Rabinson J., Meltcer S., Zohav E., Gemer O., Anteby E.Y., and Orvieto R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in-vitro fertilization outcome. Fertil Steril 89 (2008) 472-474
9. Orvieto R., Rabinson J., Meltcer S., Gemer O., Anteby E.Y., and Zohav E. Does physicians' experience influence IVF success in patients undergoing controlled ovarian stimulation with GnRH-antagonists?. Fertil Steril 89 (2008) 736-737